Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes.
作者信息
Miners John O, Day Richard O
出版信息
Br J Clin Pharmacol. 2007 Mar;63(3):380-1; author reply 381-2. doi: 10.1111/j.1365-2125.2006.02737.x. Epub 2006 Aug 2.
Abstract
摘要
相似文献
1
Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes.
Br J Clin Pharmacol. 2007 Mar;63(3):380-1; author reply 381-2. doi: 10.1111/j.1365-2125.2006.02737.x. Epub 2006 Aug 2.
2
Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid.
Br J Clin Pharmacol. 2005 Dec;60(6):623-8. doi: 10.1111/j.1365-2125.2005.02495.x.
3
[Non steroidal anti-inflammatory drugs].
Nihon Rinsho. 2004 Dec;62 Suppl 12:399-402.
4
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
BMJ. 2005 Dec 3;331(7528):1310-6. doi: 10.1136/bmj.331.7528.1310.
5
Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding.
Gastroenterology. 2007 Dec;133(6):2071-2; author reply 2072-3. doi: 10.1053/j.gastro.2007.10.015.
6
[Selective COX-2 inhibitors--side effects in relation to non-specific non-steroidal anti-inflammatory drugs].
Ugeskr Laeger. 2004 Dec 6;166(50):4581-4.
7
[Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application].
Di Yi Jun Yi Da Xue Xue Bao. 2002 Feb;22(2):184-6.
8
Cardiovascular toxicity of nonsteroidal anti-inflammatory drugs: moving beyond cyclooxygenase selectivity.
Expert Rev Clin Pharmacol. 2011 May;4(3):299-302. doi: 10.1586/ecp.11.12.
9
Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?
Ann Rheum Dis. 2005 Oct;64(10):1523-4. doi: 10.1136/ard.2005.042945. Epub 2005 Jul 13.
10
Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?
Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S27-36.
本文引用的文献
1
Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid.
Br J Clin Pharmacol. 2005 Dec;60(6):623-8. doi: 10.1111/j.1365-2125.2005.02495.x.
2
Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes.
Drug Metab Dispos. 2006 Feb;34(2):199-202. doi: 10.1124/dmd.105.005652. Epub 2005 Oct 28.
3
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
Pharmacogenet Genomics. 2005 Oct;15(10):713-21. doi: 10.1097/01.fpc.0000174786.85238.63.
4
CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Cancer Res. 2001 May 1;61(9):3566-9.
5
Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications.
Pharmacogenetics. 1997 Dec;7(6):485-95. doi: 10.1097/00008571-199712000-00007.
6
The metabolism of aspirin in man: a population study.
Xenobiotica. 1986 Mar;16(3):239-49. doi: 10.3109/00498258609043527.
7
Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.
Clin Pharmacokinet. 1989 Nov;17(5):327-44. doi: 10.2165/00003088-198917050-00003.
8
Pharmacokinetics of salicylate in man.
Drug Metab Rev. 1979;9(1):3-19. doi: 10.3109/03602537909046431.
Zotero 插件